Cargando…

Increase in negative charge of (68)Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules

Upregulation of the human epidermal growth factor receptor type 3 (HER3) is a common mechanism to bypass HER-targeted cancer therapy. Affibody-based molecular imaging has the potential for detecting and monitoring HER3 expression during treatment. In this study, we compared the imaging properties of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rinne, Sara S., Dahlsson Leitao, Charles, Gentry, Joshua, Mitran, Bogdan, Abouzayed, Ayman, Tolmachev, Vladimir, Ståhl, Stefan, Löfblom, John, Orlova, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881397/ https://www.ncbi.nlm.nih.gov/pubmed/31776413 http://dx.doi.org/10.1038/s41598-019-54149-3

Ejemplares similares

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of (68)Ga-Labeled Tracers
por: Dahlsson Leitao, Charles, et al.
Publicado: (2019)

HER3 PET Imaging: (68)Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to (89)Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
por: Rinne, Sara S., et al.
Publicado: (2021)

Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111
por: Rinne, Sara S., et al.
Publicado: (2019)

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake
por: Rosestedt, Maria, et al.
Publicado: (2019)

Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
por: Altai, Mohamed, et al.
Publicado: (2018)

Affibody-mediated PET imaging of HER3 expression in malignant tumours
por: Rosestedt, Maria, et al.
Publicado: (2015)

Preclinical Evaluation of [(68)Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors
por: Oroujeni, Maryam, et al.
Publicado: (2018)

Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model
por: Dahlsson Leitao, Charles, et al.
Publicado: (2020)

Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2022)

In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct
por: Bass, Tarek Z., et al.
Publicado: (2017)

Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with (99m)Tc using a peptide-based cysteine-containing chelator
por: Andersson, Ken G., et al.
Publicado: (2016)

Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts
por: Garousi, Javad, et al.
Publicado: (2019)

Influence of composition of cysteine-containing peptide-based chelators on biodistribution of (99m)Tc-labeled anti-EGFR affibody molecules
por: Oroujeni, Maryam, et al.
Publicado: (2018)

Influence of Macrocyclic Chelators on the Targeting Properties of (68)Ga-Labeled Synthetic Affibody Molecules: Comparison with (111)In-Labeled Counterparts
por: Strand, Joanna, et al.
Publicado: (2013)

Cyclic versus Noncyclic Chelating Scaffold for (89)Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression
por: Summer, Dominik, et al.
Publicado: (2017)

(66)Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [(66)Ga]Ga-NOTA-PEG(2)-RM26
por: Rinne, Sara S., et al.
Publicado: (2021)

PET imaging of epidermal growth factor receptor expression in tumours using (89)Zr-labelled ZEGFR:2377 affibody molecules
por: GAROUSI, JAVAD, et al.
Publicado: (2016)

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model
por: Mitran, Bogdan, et al.
Publicado: (2018)

Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches
por: Güler, Rezan, et al.
Publicado: (2020)

The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule
por: Garousi, Javad, et al.
Publicado: (2017)

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT
por: Sörensen, Jens, et al.
Publicado: (2016)

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody–DM1 Drug Conjugates
por: Ding, Haozhong, et al.
Publicado: (2019)

Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy
por: Vorobyeva, Anzhelika, et al.
Publicado: (2018)

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [(68)Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation
por: Lundmark, Fanny, et al.
Publicado: (2023)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2019)

The Use of a Non-Conventional Long-Lived Gallium Radioisotope (66)Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule
por: Oroujeni, Maryam, et al.
Publicado: (2021)

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
por: Lundmark, Fanny, et al.
Publicado: (2020)

Cellular Effects of HER3-Specific Affibody Molecules
por: Göstring, Lovisa, et al.
Publicado: (2012)

Preclinical Evaluation of a New Format of (68)Ga- and (111)In-Labeled Affibody Molecule Z(IGF-1R:4551) for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT
por: Liu, Yongsheng, et al.
Publicado: (2022)

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart
por: Oroujeni, Maryam, et al.
Publicado: (2019)

Affibody Molecules as Targeting Vectors for PET Imaging
por: Tolmachev, Vladimir, et al.
Publicado: (2020)

Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer
por: Mitran, Bogdan, et al.
Publicado: (2019)

Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification
por: Malm, Magdalena, et al.
Publicado: (2013)

Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

Correction: Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification
por: Malm, Magdalena, et al.
Publicado: (2013)

Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
por: Strand, Joanna, et al.
Publicado: (2015)

Application of a Novel (68)Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients
por: Miao, Haitao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ka1j9gavah83cdfenpbgldvnme